版本:
中国

BRIEF-Abbvie submits supplemental new drug application for ibrutinib

April 4 Abbvie Inc-

* Abbvie announces ibrutinib (imbruvica®) supplemental new drug application for previously treated chronic graft-versus-host-disease (cgvhd) accepted for review by U.S. FDA

* Abbvie Inc says imbruvica is jointly developed and commercialized by Pharmacyclics Llc, an Abbvie company, and Janssen Biotech, inc Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐